BSE - Delayed Quote INR

Akums Drugs and Pharmaceutical (AKUMS.BO)

Compare
550.90
-14.80
(-2.62%)
At close: January 27 at 3:29:00 PM GMT+5:30
Currency in INR All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
39,207,440.00
40,196,820.00
34,747,640.00
36,468,340.00
26,951,670.00
Cost of Revenue
24,789,540.00
25,822,240.00
23,074,700.00
23,778,330.00
17,157,120.00
Gross Profit
14,417,900.00
14,374,580.00
11,672,940.00
12,690,010.00
9,794,550.00
Operating Expense
11,255,560.00
10,775,590.00
9,759,800.00
9,467,920.00
7,498,250.00
Operating Income
3,162,340.00
3,598,990.00
1,913,140.00
3,222,090.00
2,296,300.00
Net Non Operating Interest Income Expense
-377,390.00
-386,150.00
-383,660.00
-120,240.00
-6,000.00
Pretax Income
2,054,590.00
-452,780.00
1,502,970.00
-1,931,970.00
1,722,610.00
Tax Provision
-779,290.00
-460,680.00
524,800.00
576,770.00
488,260.00
Net Income Common Stockholders
2,825,840.00
7,900.00
978,170.00
-2,508,740.00
1,227,050.00
Diluted NI Available to Com Stockholders
2,825,840.00
7,900.00
978,170.00
-2,508,740.00
1,227,050.00
Basic EPS
18.46
0.05
6.21
-15.94
7.80
Diluted EPS
18.46
0.05
6.21
-15.94
7.80
Basic Average Shares
153,102.06
157,394.00
157,394.00
157,394.00
157,394.00
Diluted Average Shares
153,102.06
157,394.00
157,394.00
157,394.00
157,394.00
Rent Expense Supplemental
--
59,770.00
34,760.00
26,480.00
37,630.00
Total Expenses
36,045,100.00
36,597,830.00
32,834,500.00
33,246,250.00
24,655,370.00
Net Income from Continuing & Discontinued Operation
2,825,840.00
7,900.00
978,170.00
-2,508,740.00
1,227,050.00
Normalized Income
3,508,221.00
2,708,927.00
1,148,542.89
1,225,582.00
1,824,577.73
Interest Income
--
119,990.00
78,800.00
46,310.00
61,440.00
Interest Expense
493,750.00
502,510.00
459,730.00
163,380.00
63,880.00
Net Interest Income
-377,390.00
-386,150.00
-383,660.00
-120,240.00
-6,000.00
EBIT
2,548,340.00
49,730.00
1,962,700.00
-1,768,590.00
1,786,490.00
EBITDA
3,892,650.00
1,306,130.00
3,090,790.00
-821,800.00
2,484,900.00
Reconciled Cost of Revenue
24,789,540.00
25,822,240.00
23,074,700.00
23,778,330.00
17,157,120.00
Reconciled Depreciation
1,344,310.00
1,256,400.00
1,128,090.00
946,790.00
698,410.00
Net Income from Continuing Operation Net Minority Interest
2,825,840.00
7,900.00
978,170.00
-2,508,740.00
1,227,050.00
Total Unusual Items Excluding Goodwill
-974,830.00
-3,858,610.00
-261,780.00
-5,149,360.00
-694,330.00
Total Unusual Items
-974,830.00
-3,858,610.00
-261,780.00
-5,019,590.00
-594,330.00
Normalized EBITDA
4,867,480.00
5,164,740.00
3,352,570.00
4,197,790.00
3,079,230.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-292,449.00
-1,157,583.00
-91,407.11
-1,544,808.00
-196,802.27
3/31/2021 - 8/6/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers